VERA - Company ID 0001831828
The table below shows Vera Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$241.10M | -$134.68M | -$92.18M | -$67.60M | -$23.71M | -$34.81M |
| Capital expenditure | $630.00K | $972.00K | $63.00K | $62.00K | $0.00 | $99.00K |
| Investing cash flow | $194.29M | -$425.03M | -$39.43M | -$70.55M | -$4.20M | -$42.00K |
| Dividends paid | - | - | - | - |
Vera Therapeutics, Inc. reported operating cash flow of -$241.10M for fiscal year 2025. That is down 79.0% from -$134.68M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$34.81M (FY 2020) to -$241.10M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | $0.00 | $13.00K | $0.00 | - | - | - |
| Financing cash flow | $308.90M | $606.67M | $133.54M | $101.93M | $53.88M | $85.29M |